Metformin: effective and safe in renal disease? (scientific article)

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Q27860882

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

Q28283679

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

Q29547282

Metformin-associated lactic acidosis: a rare or very rare clinical entity?

Q33603791

Metformin's contraindications should be contraindicated.

Q33920606

Lactic acidosis in metformin therapy: searching for a link with metformin in reports of 'metformin-associated lactic acidosis'.

Q33951985

High anion gap metabolic acidosis in suicide: don't forget metformin intoxication--two patients' experiences

Q34154506

Metformin and lactic acidosis: cause or coincidence? A review of case reports

Q34544806

Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus

Q34737078

Biguanide-associated lactic acidosis. Case report and review of the literature

Q35534961

The phantom of lactic acidosis due to metformin in patients with diabetes

Q35818985

Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial

Q36454820

Metformin and the sulphonylureas: the comparative risk

Q39850311

Metformin--an update

Q40717191

Incidence and Risk Factors for Serious Hypoglycemia in Older Persons Using Insulin or Sulfonylureas

Q42055798

Contraindications to metformin therapy in patients with Type 2 diabetes--a population-based study of adherence to prescribing guidelines

Q43687476

Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy

Q43894642

Metformin and serious adverse effects

Q44728140

Kidney function and age are both predictors of pharmacokinetics of metformin.

Q46035485

Lactic Acidosis Rates in Type 2 Diabetes

Q50634893

[The relatively frequent incidence of severe sulfonylurea-induced hypoglycemia in the last 25 years in Switzerland. Results of 2 surveys in Switzerland in 1969 and 1984]

Q70037443

Metformin-associated mortality in U.S. studies

Q71073971

P433

issue

P921

main subject

metformin

Q19484

P304

page(s)

411-417

P577

publication date

2008-01-01

P13046

publication type of scholarly work

review article

Q7318358

P1433

published in

International Urology and Nephrology

Q15763616

P1476

title

Metformin: effective and safe in renal disease?

P478

volume

Reverse relations

cites work (P2860)

Q50573885	Cardiovascular events in chronic dialysis patients: emphasizing the importance of vascular disease prevention
Q34620565	Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
Q37718287	Comparative effectiveness of oral diabetes drug combinations in reducing glycosylated hemoglobin
Q48304274	Could metformin be used in patients with advanced chronic kidney disease?
Q37616135	Erythrocyte metformin levels in patients with type 2 diabetes and varying severity of chronic kidney disease
Q37877781	Experimental gentamicin nephrotoxicity and agents that modify it: a mini-review of recent research
Q82636138	Expert consensus on management of diabetic patients with impairment of renal function
Q45960640	Glycaemic Control after Metformin Discontinuation in Diabetic Patients with a Declining Renal Function.
Q86364087	Hypoglycemic treatment in type 2 diabetes patients suffering from moderate to severe renal failure in France. Aim of the study
Q46091360	Impact of acute kidney injury on metformin-associated lactic acidosis
Q45122634	Importance of creatinine clearance for drug dosing in nursing home residents
Q33792375	Management of diabetes mellitus in patients with chronic kidney disease
Q90172604	Metformin Can Alleviate the Symptom of Patient with Diabetic Nephropathy Through Reducing the Serum Level of Hcy and IL-33
Q38202947	Metformin in chronic kidney disease: time for a rethink
Q38130189	Metformin therapy and kidney disease: a review of guidelines and proposals for metformin withdrawal around the world
Q56888943	Metformin use in the first year after kidney transplant, correlates, and associated outcomes in diabetic transplant recipients: A retrospective analysis of integrated registry and pharmacy claims data
Q34571105	Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins
Q37982112	Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment
Q44576328	Severe Lactic Acidosis and Acute Pancreatitis Associated with Cimetidine in a Patient with Type 2 Diabetes Mellitus Taking Metformin
Q37676827	Slowing the progression of chronic kidney disease
Q37850217	Special considerations for treatment of type 2 diabetes mellitus in the elderly
Q37634244	The treatment of type 2 diabetes
Q36522911	Use of Renally Inappropriate Medications in Older Veterans: A National Study
Q22241290	Use of metformin in the setting of mild-to-moderate renal insufficiency

P356	DOI	10.1007/S11255-008-9371-6
P8608	Fatcat ID	release_tg4tf2qcdjhktb74zsjwuh27ty
P698	PubMed publication ID	18368503